Compare Braze Inc (BRZE) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Braze Inc vs Gilead Sciences, Inc. — how do they compare? Braze Inc trades at $27.77 (market cap $3.18B), while Gilead Sciences, Inc. trades at $135.19 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 52.9× Braze Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Braze Inc pays none. Which is the better fit depends on your goals.
| BRZE | GILD | |
|---|---|---|
Market Cap | $3.18B | $168.35B |
Sector | Technology | Health |
52-Week High | $36.19 | $155.80 |
52-Week Low | $15.79 | $110.56 |
Enterprise Value | $2.87B | $191.42B |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
